Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CIMETIDINE

All products: general benefit

Other products in the same Health Canada class (A02B, A02BA) — coverage varies; not interchangeable

  • Famotidine (Pepcid): general benefit, Not a benefit
  • Nizatidine (Axid): general benefit
  • Ranitidine (Zantac): general benefit, Not a benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

Cimetidine · DIN 00487872 · 300mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cimetidine · DIN 00487872 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-10-23 · brand CIMETIDINE · ATC A02BA01 CIMETIDINE · form Tablet · route Oral · ingredients CIMETIDINE 300 MG · company Masterfeeds, division of agp · schedule Prescription
Check this DIN again · Health Canada product record

Cimetidine: Formulary list price $0.3423/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3423 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5196 · Verify on the e-Formulary ↗ (DIN 00487872)

Source record
DIN 00487872: Cimetidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000003; group id 674; item number 1684; lccId None; manufacturer id AAP Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3423; ministry $0.3423 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00487872 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5196
Interchangeable products
Tagamet · DIN 01916815 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CIMETIDINE (Cimetidine) is primary therapy - for conditions where the inhibition of gastric acid secretion is likely to be beneficial such as: • Duodenal ulcer therapy. • Non-malignant gastric ulcer therapy. • Prophylaxis of recurrent duodenal or gastric ulcer. • Gastroesophageal reflux disease. • Pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis and multiple endocrine adenomas. • Treatment of NSAID-induced lesions (ulcers, erosions) and gastrointestinal symptoms and prevention of their recurrence. • Adjunctive therapy in the management of cystic fibrosis in children. 1.1 Pediatrics Pediatrics (16 to 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of cimetidine in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use. See 1 INDICATIONS, 4.2 Recommended Dose and Dosage Adjustment, and 8.1 Adverse Reaction Overview. 1.2 Geriatrics Geriatrics (>65 years of age): No data are available to Health Canada; however, evidence suggests that use in the geriatric population is associated with differe… https://pdf.hres.ca/dpd_pm/00064698.PDF PM date: DEC 31, 1982 Source product: CIMETIDINE; DIN 00487872; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.